Published in Gene Therapy Weekly, January 27th, 1997
The merger is expected to significantly strengthen key research and development programs, open up prospects for new forms of gene therapies, and expand corporate partnering opportunities. "This merger will enhance our competitive position and our ability to make gene therapy a commercial reality," said Stephen A. Sherwin, M.D., Cell Genesys.
"Gene therapy offers extraordinary opportunities to intervene at the most basic levels of the disease process...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly